<DOC>
	<DOCNO>NCT02952937</DOCNO>
	<brief_summary>The purpose clinical trial ( 1 ) evaluate bioequivalence ( BE ) GLA5PR GLARS-NF3 tablet 300mg administer regular diet relative GLA5PR GLARS-NF1 tablet 300mg administer regular diet ( 2 ) determine safety tolerability single dose GLA5PR GLARS-NF3 tablet 300mg administer regular diet GLA5PR GLARS-NF1 tablet 300mg administer regular diet .</brief_summary>
	<brief_title>Bioequivalence Study Two Formulations Pregabalin CR ( Controlled-release ) Table 300 mg</brief_title>
	<detailed_description>To assess single dose pharmacokinetics , safety , tolerability GLA5PR GLARS-NF3 tablet 300mg administer regular diet relative GLA5PR GLARS-NF1 tablet 300mg administer regular diet . IP administer 1 tablet ( 300mg ) day ( QD ) even meal .</detailed_description>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Healthy male subject , time screening , age old 19 year . Subjects BMI 17.5kg/m2 less 30.5kg/m2 body weight 55kg . There congenital disease within 3 year chronic disease . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead electrocardiogram ( ECG ) clinical laboratory test . Subjects sign date informed consent form ( approved IRB ) understand fully hear detailed explanation clinical trial Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . A subject history gastrointestinal disease ( e.g. , Crohn 's disease , acute chronic pancreatitis , others ) surgery ( except simple appendectomy repair hernia ) , influence absorption investigational product . A subject follow clinical laboratory test result ☞ Liver Function Test ( AST , ALT ) &gt; three time upper limit normal range History regular alcohol consumption exceed 210g/week ( 12g = 125 mL wine , 10g = 250 mL beer , 10g = 50 mL hard liquor ) within 6 month Screening . A subject participate clinical trial medication within 3 month prior first administration investigational product . ( The end date another clinical trial base last day administration ) A subject follow vital sign result sit position time screening : SBP ≤ 90 mmHg DBP ≤ 60 mmHg . A subject history drug abuse positive urine drug screen drug abuse A subject take drug induce suppress drugmetabolizing enzyme within 30 day prior investigational product administration . A smoker consume 20 cigarettes/days A subject take ethicalthecounter drug take overthecounter drug within 10days investigational product administration A subject donate whole blood within 2 month blood component within 1 month prior investigational product administration Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation . A subject unable take regular diet study period . Abnormal diet may affect absorption , distribution , metabolism excretion drug History sensitivity pregabalin , gabapentin , alpha2 delta ligand . Evidence hereditary disease , include galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption . Unwilling unable comply Lifestyle Guidelines describe protocol . A subject eligible study due reason investigator ' judgment .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Neuralgia , Postherpetic</keyword>
	<keyword>Postherpetic Neuralgia</keyword>
	<keyword>Diabetic Neuropathies</keyword>
	<keyword>Diabetic Neuralgia</keyword>
	<keyword>Diabetic Polyneuropathy</keyword>
	<keyword>Diabetic Neuropathy , Painful</keyword>
	<keyword>Neuralgia</keyword>
	<keyword>Neuropathic Pain</keyword>
	<keyword>Pregabalin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Bioequivalent</keyword>
</DOC>